Orphazyme A/S ADR (ORPH)
$0.87
0.00 (0.00%)
ORPH Stock Quote Delayed 30 Minutes
Dear ORPH Stock Fans, Mark Your Calendars for March 31
After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
Day's Range
-
52-Week Range
-
Dividend & Yield
N/A (N/A)
ORPH Stock Predictions, Articles, and Orphazyme A/S ADR News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! We're starting off the trading week with a breakdown of the biggest pre-market stock movers for Monday!
ORPH Stock Alert: What’s Going on With Red-Hot Orphazyme Today?
Today, retail investors and traders appear willing to put some big money down on Orphazyme and ORPH stock as a potential short-squeeze play.
Dear ORPH Stock Fans, Here Is the Latest Trial News You Should Be Cheering
Today, ORPH stock is trading significantly higher after the company announced some positive clinical trial data for its lead drug candidate.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's a new week and that means it's time for us to start it off with a look at the biggest pre-market stock movers for Monday!
Dear ORPH Stock Fans, Mark Your Calendars for August 31
Today, investors appear to be pricing some positive news and a potential short squeeze into ORPH stock, as Orphazyme shoots higher.
Orphazyme Stock Is a Dead-End for Investors After FDA Rejection
ORPH stock has a virtually impossible task ahead of it in picking itself after FDA's rejection of the Danish biopharma's Arimoclomol drug.
Orphazyme’s Massive Price Appreciation Won’t Be Captured Again
ORPH stock multiplied overnight to lofty highs, but it clearly won't happen again due to its very small market capitalization.
Orphazyme A/S May Look Like a Long Shot, but Things Aren’t That Dire
How far could ORPH stock climb if it gets squeezed? Maybe not back above $77 per share. But, a move back to $15-$20 per share could be attainable. For investors with a healthy risk appetite, and a stomach for volatility, consider it a buy at today's prices (around $7.25 per share).
Despite FDA Disappointment, All Hope Isn’t Lost for Orphazyme
Resilient ORPH stock bulls managed to hold their ground even amid a regulatory setback. Could a major rally be just around the corner?
ORPH Stock: The Big News That Has Red-Hot Orphazyme Gaining Today
Two key announcements from Orphazyme are sending shares of ORPH stock higher today, as investors continue to reprice this biopharma stock.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
Short Squeeze Stocks: CLOV, AEI and 3 Other Stocks Experts Think Are Ready to Pop
Short squeeze stocks have been targeted quite a bit lately as retail traders tackle them in an effort to push out hedge funds.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Welcome to another busy day of trading, investor! We're starting the day off with a look at the biggest pre-market stock movers for Thursday.
ORPH Stock: Why Orphazyme Is Gaining Today Despite FDA Disappointment
Today's massive upward move in ORPH stock appears to be the result of a disclosed stake in the company of more than 5% from Goldman Sachs.
Assess Biotech Landscape Hazards Before Trading Orphazyme Stock
ORPH stock, a play on Niemann-Pick disease, generated big headlines for its even bigger price action. But you want to do some serious due diligence before gambling on this biotech stock.
ORPH Stock: The FDA News That Has Orphazyme Plunging Today
ORPH stock is taking a plunge on Friday after the FDA told Orphazyme it needed more data on its lead drug candidate.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading for the week and we're kicking it off right with a look at the pre-market stock movers for Friday!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off the day with a look at the biggest pre-market stock movers for Thursday and it includes loads of medical stocks.
